Timothy Edward Lee Sells 22,355 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 22,355 shares of Invivyd stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $16,095.60. Following the completion of the transaction, the insider owned 197,362 shares of the company’s stock, valued at approximately $142,100.64. This trade represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Timothy Edward Lee also recently made the following trade(s):

• On Tuesday, August 18th, Timothy Edward Lee sold 18,425 shares of Invivyd stock. The shares were sold at an average price of $0.84, for a total value of $15,477.00.

Invivyd Stock Performance

Shares of IVVD opened at $0.96 on Thursday. Invivyd, Inc. has a 52-week low of $0.48 and a 52-week high of $3.07. The stock’s 50-day simple moving average is $0.77 and its 200 day simple moving average is $1.23. The stock has a market capitalization of $282.82 million, a price-to-earnings ratio of -2.91 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last posted its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The company had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. On average, research analysts forecast that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IVVD has been the subject of several recent analyst reports. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. BTIG Research restated a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a report on Tuesday. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Key Invivyd News

Here are the key news stories impacting Invivyd this week:

• Positive Sentiment: Several research firms maintain Buy ratings on Invivyd, and the stock’s average analyst price target remains substantially above its current trading range. Institutional ownership is also significant, with investors holding about 70% of the outstanding shares. MarketBeat Invivyd analyst and institutional data
• Neutral Sentiment: Robert Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold Invivyd shares on August 17 or 18 at approximately $0.72 or $0.84. The transactions reduced their individual holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings indicate that the sales were made to cover tax-withholding obligations associated with vested equity awards. That makes them less bearish than discretionary open-market sales intended to reduce exposure.
• Negative Sentiment: The unusually broad participation by multiple insiders could still create a short-term sentiment overhang, particularly for Invivyd’s relatively small market capitalization. Investors also continue to face fundamental risks: the company recently missed quarterly earnings expectations, reported a net loss, and remains dependent on the development and commercialization of its antibody-based infectious-disease pipeline.

Institutional Investors Weigh In On Invivyd

A number of large investors have recently added to or reduced their stakes in IVVD. Chicago Partners Investment Group LLC bought a new stake in Invivyd during the first quarter worth about $25,000. Courier Capital LLC bought a new position in shares of Invivyd during the 4th quarter valued at about $25,000. Bronte Capital Management Pty Ltd. bought a new position in shares of Invivyd during the 4th quarter valued at about $27,000. DRW Securities LLC purchased a new position in shares of Invivyd during the 4th quarter valued at about $27,000. Finally, ProShare Advisors LLC purchased a new position in shares of Invivyd during the 4th quarter valued at about $30,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.